Related references
Note: Only part of the references are listed.The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection
Benjamin P. Linas et al.
ANNALS OF INTERNAL MEDICINE (2015)
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Soumitri Barua et al.
ANNALS OF INTERNAL MEDICINE (2015)
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
Zobair Younossi et al.
DIGESTIVE AND LIVER DISEASE (2014)
Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Sofosbuvir-Containing Regimens
Zobair M. Younossi et al.
HEPATOLOGY (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Estimating HCV Prevalence at the State Level: A Call to Increase and Strengthen Current Surveillance Systems
Rachel Hart-Malloy et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2013)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Share Paper
